Human B7-2 (CD86) (C-Fc-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P-) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of Human CD86 protein exceeds 90%.
Human CTLA4 (C-Fc) is coated at 2 ug/mL (200 ng/well). Biotinylated Human B7-2 (CD86) (C-Fc-Avi) can bind human CTLA-4 in the dose dependent manner with ED50 in the range of 15-50 ng/mL.
Cat #
Size
Price
Quantity
817503
25 ug
$245
817504
100 ug
$595
Product Details
Application
ELISA, BLI
Format
Liquid, Biotinylated
Expression Host
CHO
Target Name
CD86, B7-2, B70, CD28LG2
Species
Human
Sources
Recombinant Human B7-2 (CD86) (Leu20-Pro247) with C-terminus Fc-Avi-tag is expressed in CHO cell. This protein was site-specifically labeled with Biotin by BirA ligase.
accession number
P05408
Molecular Weight
The protein has a predicted molecular weight of 54.2 kDa. Under DTT-reducing conditions, it migrates at approximately 75 kDa on SDS-PAGE.
Affinity Tag
C-Fc-Avi
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
CD86 (B7-2) is a member of the immunoglobulin superfamily, expressed predominantly as a monomer on cell surfaces, and interacts with co-stimulatory receptors CD28 and CTLA-4 on T cells. This interaction regulates T cell activation, tolerance, cytokine production, and the generation of cytotoxic T lymphocytes (CTL). CD86 plays a critical role in promoting B and T helper cell interactions, supporting B cell proliferation and IgG secretion, particularly in B cell lymphomas. It also contributes to the development of a mature antigen-presenting cell (APC) repertoire, enhancing APC function and survival. CD86 is involved in chronic hemodialysis, allergic pulmonary inflammation, arthritis, and antiviral responses, positioning it as a potential target for immune therapies.
Human B7-2 (CD86) (C-Fc-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P-) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of Human CD86 protein exceeds 90%.
Human CTLA4 (C-Fc) is coated at 2 ug/mL (200 ng/well). Biotinylated Human B7-2 (CD86) (C-Fc-Avi) can bind human CTLA-4 in the dose dependent manner with ED50 in the range of 15-50 ng/mL.
